Eurofins-Cerep SA engages in the provision of preclinical drug research services. The firm’s BioPrint, allows the modeling of clinical effects of drug candidates from molecular properties. Its services include compound management, high-throughput screening, in vitro safety profiling, assay development, and profile design. The company was founded on December 20, 1989 and is headquartered in Celle l'Evescault, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company